Molecular basis of myelodysplastic/myeloproliferative neoplasms
- PMID: 19996113
- PMCID: PMC2791938
- DOI: 10.3324/haematol.2009.014001
Molecular basis of myelodysplastic/myeloproliferative neoplasms
Abstract
The World Health Organization classification of tumors of hematopoietic and lymphoid tissues includes within myeloid neoplasms the category myelodysplastic/myeloproliferative neoplasms. In this perspective article Drs. Reiter, Invernizzi, Cross and Cazzola discuss our present knowledge of the molecular basis of these disorders. See related paper on page 1676.
Figures



Comment on
-
TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia.Haematologica. 2009 Dec;94(12):1676-81. doi: 10.3324/haematol.2009.011205. Epub 2009 Oct 1. Haematologica. 2009. PMID: 19797729 Free PMC article.
Similar articles
-
Targeted re-sequencing of TET2 in Taiwanese patients with myelodysplastic/myeloproliferative neoplasms.Med Oncol. 2016 Aug;33(8):92. doi: 10.1007/s12032-016-0808-y. Epub 2016 Jul 14. Med Oncol. 2016. PMID: 27418193 No abstract available.
-
A meta-analysis of TET2 mutations shows a distinct distribution pattern in de novo acute myeloid leukemia and chronic myelomonocytic leukemia.Leuk Lymphoma. 2012 Jun;53(6):1230-3. doi: 10.3109/10428194.2011.639878. Epub 2012 Apr 2. Leuk Lymphoma. 2012. PMID: 22080757 No abstract available.
-
Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia.Mod Pathol. 2017 Sep;30(9):1213-1222. doi: 10.1038/modpathol.2017.45. Epub 2017 May 26. Mod Pathol. 2017. PMID: 28548124
-
Myelodysplastic/myeloproliferative neoplasms: a disease in need of recognition.Future Oncol. 2017 Jan;13(2):117-120. doi: 10.2217/fon-2016-0310. Epub 2016 Sep 27. Future Oncol. 2017. PMID: 27676208 Review. No abstract available.
-
Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes.Curr Opin Hematol. 2014 Mar;21(2):131-40. doi: 10.1097/MOH.0000000000000021. Curr Opin Hematol. 2014. PMID: 24378705 Review.
Cited by
-
NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy.Cell Rep Med. 2023 Dec 19;4(12):101329. doi: 10.1016/j.xcrm.2023.101329. Cell Rep Med. 2023. PMID: 38118408 Free PMC article.
-
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.Nat Genet. 2013 Jan;45(1):18-24. doi: 10.1038/ng.2495. Epub 2012 Dec 9. Nat Genet. 2013. PMID: 23222956 Free PMC article.
-
Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.Haematologica. 2011 Mar;96(3):349-52. doi: 10.3324/haematol.2010.030023. Haematologica. 2011. PMID: 21357714 Free PMC article. No abstract available.
-
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.Lancet Haematol. 2017 Jul;4(7):e317-e324. doi: 10.1016/S2352-3026(17)30088-1. Epub 2017 Jun 8. Lancet Haematol. 2017. PMID: 28602585 Free PMC article. Clinical Trial.
-
Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts.Haematologica. 2013 Apr;98(4):576-83. doi: 10.3324/haematol.2012.071506. Epub 2012 Oct 12. Haematologica. 2013. PMID: 23065512 Free PMC article.
References
-
- Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.
-
- Vardiman JW, Brunning RD, Arber DA, Le Beau MM, Porwit A, Tefferi A, et al. Introduction and overview of the classification of the myeloid neoplasms. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. pp. 18–30.
-
- Orazi A, Bennet JM, Germing U, Brunning R, Bain BJ, Thiele J. Chronic myelomonocytic leukaemia. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: 2008. pp. 76–9.
-
- Vardiman J, Bennet JM, Bain BJ, Brunning R, Thiele J. Atypical chronic myeloid leukaemia, BCR-ABL1 negative. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008. pp. 80–1.
-
- Baumann I, Bennet JM, Niemeyer CM, Thiele J, Shannon K. Juvenile myelomonocytic leukaemia. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC; 2008. pp. 82–4.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources